Panitumumab Plus Neoadjuvant Chemotherapy for Primary HER2 - Negative Inflammatory Breast Cancer

This single-arm, open-label trial evaluates the safety and efficacy of the anti–epidermal growth factor receptor antibody panitumumab plus neoadjuvant chemotherapy (nab-paclitaxel and carboplatin followed by fluorouracil, epirubicin, and cyclophosphamide) in patients with primary HER2-negative inflammatory breast cancer.

https://ift.tt/2M5Drap